Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.22+0.09 (+2.18%)
Close on Nov 17, 2026Market cap $13.58MP/E –Yield –
Passage BIO operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Passage BIO's operating cash flow for the twelve months ending Jun 30, 2026 was -$33.50M. For fiscal 2025 it was -$31.51M. The highest annual figure on record is -$31.51M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$31.51M | – |
| FY2024 | Dec 31, 2024 | -$47.96M | – |
| FY2023 | Dec 31, 2023 | -$78.26M | – |
| FY2022 | Dec 31, 2022 | -$118.21M | – |
| FY2021 | Dec 31, 2021 | -$126.88M | – |
| FY2020 | Dec 31, 2020 | -$80.52M | – |
| FY2019 | Dec 31, 2019 | -$39.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.45M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$44.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$41.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.72M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.78M | – |
| Q1 FY2019 | Mar 31, 2019 | -$214.00K | – |
See a number that looks wrong?